Guerbet Valuation Multiples

Guerbet Overview

About Guerbet

Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.

Founded

1926

HQ

Employees

981

Website

guerbet.com

Sectors

Medical DevicesBiopharmaceuticalsBioTechLongevity

Financials (LTM)

Revenue: $905M

EBITDA: $102M

EV

$496M

Valuation Multiples

Multiples.vc

Start free trial

Guerbet Financials

Guerbet reported last 12-month revenue of $905M and EBITDA of $102M.

In the same LTM period, Guerbet generated $102M in EBITDA and had net loss of ($89M).

Guerbet P&L

In the most recent fiscal year, Guerbet reported revenue of $940M and EBITDA of $104M.

Guerbet expects next 12-month revenue of XXX and NTM EBITDA of XXX

Guerbet Stock Performance

Guerbet has current market cap of $146M, and enterprise value of $496M.

Guerbet's stock price is $11.60.

Guerbet Valuation Multiples

Guerbet trades at 0.5x EV/Revenue multiple, and 4.9x EV/EBITDA.

Guerbet Financial Valuation Multiples

As of April 20, 2026, Guerbet has market cap of $146M and EV of $496M.

Equity research analysts estimate Guerbet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Guerbet has a P/E ratio of (1.6x).

Guerbet Margins & Growth Rates

Guerbet's revenue in the last 12 month grew by 1%.

Guerbet's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.7M for the same period.

Guerbet's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Guerbet's rule of X is 1% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Guerbet Public Comps

See public comps and valuation multiples for other Medical Devices and Biopharmaceuticals comps.

Guerbet M&A Activity

Guerbet acquired XXX companies to date.

Last acquisition by Guerbet was on XXXXXXXX, XXXXX. Guerbet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Guerbet Investment Activity

Guerbet invested in XXX companies to date.

Guerbet made its latest investment on XXXXXXXX, XXXXX. Guerbet invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).